You searched for: «【✈️ Telegram ID: KPU77】 성피찾기 성인피씨방 안전 보장 100% 알거래 중개소 리스트 - 양주»
Results 106 - 110 of 156
Page 22 of 32
  1. Media
  2. Newsroom

Galderma announces publication of phase 2b trial results demonstrating the rapid and long-lasting benefits of nemolizumab in clinical trial subjects with uncontrolled atopic dermatitis

  1. Media
  2. Newsroom

Galderma receives FDA approval for Restylane® Contour for cheek augmentation and correction of midface contour deficiencies

Galderma’s first and only product in the U.S. to use proprietary XpresHAn Technology™ for the cheeks

 

  1. Media
  2. Newsroom

Galderma expands Restylane® portfolio in Japan with launch of OBT™ hyaluronic acid injectables Restylane Defyne™ and Refyne™

  • Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2 
  • This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of
  1. Media
  2. Newsroom

Galderma Announces Publication of Pivotal Phase 3 PERFECT 1 and PERFECT 2 Clinical Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne in the Journal of the American Academy of Dermatology

Both Studies of Next-Generation Topical Retinoid for Acne on the Face, Chest and Back Met All Primary and Secondary Efficacy Endpoints

 

  1. Media
  2. Newsroom

Galderma announces new data demonstrating the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis

Results from transcriptomic (RNA Gene Expression) data now published in the Journal of Allergy and Clinical Immunology:

Results 106 - 110 of 156
Page 22 of 32